<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04442919</url>
  </required_header>
  <id_info>
    <org_study_id>METHANE</org_study_id>
    <nct_id>NCT04442919</nct_id>
  </id_info>
  <brief_title>Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris</brief_title>
  <acronym>METHANE</acronym>
  <official_title>Influence of METHoxyflurane on ANtiplatelet Effect of Ticagrelor in Patients With Unstable Angina Pectoris - METHANE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Collegium Medicum w Bydgoszczy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Collegium Medicum w Bydgoszczy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate differences in the pharmacokinetics and&#xD;
      pharmacodynamics of ticagrelor and its active metabolite in patients who received ticagrelor&#xD;
      followed with methoxyflurane versus ticagrelor followed with morphine or ticagrelor alone due&#xD;
      to unstable angina pectoris&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Results of the IMPRESSION trial published in 2015 proved that morphine use in patients with&#xD;
      acute coronary syndromes (ACS) is associated with undesirable impact on pharmacokinetics (PK)&#xD;
      and pharmacodynamics (PD) of ticagrelor. Despite that, morphine is still a standard analgesic&#xD;
      treatment in ACS patients and it should not be routinely withdrawn. Based on contemporary&#xD;
      knowledge, morphine, acting via mi-opioid receptors, was found to inhibit gastrointestinal&#xD;
      motility or induce adverse effects such as nausea or vomiting.&#xD;
&#xD;
      We decided to design a clinical study aiming to evaluate the impact of methoxyflurane on PD&#xD;
      of ticagrelor in patients diagnosed with unstable angina pectoris (UA). Methoxyflurane is an&#xD;
      inhaled anesthetic, registered in Poland in emergency medicine for pain alleviation in trauma&#xD;
      patients. The drug was widely used in 1960s to induce general anesthesia, however its&#xD;
      clinical utility was reduced with the development of novel anesthetic agents. Taking into&#xD;
      account its different mechanism of action, it can be presumed that, contrary to morphine, no&#xD;
      respiratory depression should be observed as well as no attenuation or delay of&#xD;
      antiaggregatory effect of ticagrelor should occur, as no interaction with mi-receptor in&#xD;
      gastrointestinal tract is related to activity of methoxyflurane.&#xD;
&#xD;
      Patients will be randomized in a 1:1:1 ratio into the study arms as follows: 1) 180 mg&#xD;
      ticagrelor (2 integral tablets of 90 mg ticagrelor) followed by 3 mg inhaled methoxyflurane,&#xD;
      2) 180 mg ticagrelor followed by 5 mg intravenous morphine, 3) 180 mg ticagrelor alone&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean platelet reactivity between the study arms</measure>
    <time_frame>6 hours</time_frame>
    <description>Mean platelet reactivity between the study arms, assessed using the Multiplate Analyzer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of high platelet reactivity patients (HPR) throughout the study period</measure>
    <time_frame>6 hours</time_frame>
    <description>the percentage of patients with high platelet reactivity throughout the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to achieve platelet reactivity below the threshold for HPR</measure>
    <time_frame>6 hours</time_frame>
    <description>Mean time required for patients to receive low platelet reactivity in each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the plasma concentration-time curve for ticagrelor and its active metabolite between the study arms</measure>
    <time_frame>6 hours</time_frame>
    <description>area under the plasma concentration-time curve for ticagrelor and its active metabolite between the study arms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Unstable Angina</condition>
  <arm_group>
    <arm_group_label>Ticagrelor followed with methoxyflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor followed with morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who received ticagrelor followed with intravenous morphine due to unstable angina</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients who received ticagrelor without any analgesia due to unstable angina</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor followed with Methoxyflurane</intervention_name>
    <description>patients who received ticagrelor followed with inhaled methoxyflurane due to unstable angina</description>
    <arm_group_label>Ticagrelor followed with methoxyflurane</arm_group_label>
    <other_name>Brilique + Penthrox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor followed with Morphine</intervention_name>
    <description>patients who received ticagrelor followed with intravenous morphine due to unstable angina</description>
    <arm_group_label>Ticagrelor followed with morphine</arm_group_label>
    <other_name>Brilique + Morphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor alone</intervention_name>
    <description>patients who received ticagrelor without any analgesia due to unstable angina</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brilique</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Diagnosis of unstable angina&#xD;
&#xD;
          -  Male or non-pregnant female, aged 18-80 years&#xD;
&#xD;
          -  Provision of informed consent for angiography and PCI&#xD;
&#xD;
          -  GRACE score &lt;140 pts&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before&#xD;
             the study enrollment&#xD;
&#xD;
          -  Current treatment with morphine or any opioid &quot;mi&quot; receptor agonist&#xD;
&#xD;
          -  Hypersensitivity to ticagrelor&#xD;
&#xD;
          -  Current treatment with oral anticoagulant or chronic therapy with low-molecular-weight&#xD;
             heparin&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  History of intracranial hemorrhage&#xD;
&#xD;
          -  Recent gastrointestinal bleeding (within 30 days)&#xD;
&#xD;
          -  History of coagulation disorders&#xD;
&#xD;
          -  Platelet count less than &lt;100 x10^3/mcl&#xD;
&#xD;
          -  Hemoglobin concentration less than 10.0 g/dl&#xD;
&#xD;
          -  History of moderate or severe hepatic impairment&#xD;
&#xD;
          -  History of major surgery or severe trauma (within 3 months)&#xD;
&#xD;
          -  Risk of bradycardic events as judged by the investigator&#xD;
&#xD;
          -  Second- or third-degree atrioventricular block during screening for eligibility&#xD;
&#xD;
          -  History of asthma or severe chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Kidney disease requiring dialysis&#xD;
&#xD;
          -  Manifest infection or inflammatory state&#xD;
&#xD;
          -  Killip class III or IV during screening for eligibility&#xD;
&#xD;
          -  Respiratory failure&#xD;
&#xD;
          -  History of severe chronic heart failure (NYHA class III or IV)&#xD;
&#xD;
          -  Concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole,&#xD;
             voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir,&#xD;
             nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin,&#xD;
             carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment&#xD;
&#xD;
          -  Body weight below 50 kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek Kubica, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Collegium Medicum w Bydgoszczy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Niezgoda, MD</last_name>
    <phone>+48 52 585 4023</phone>
    <email>piotr.niezgoda1986@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiology Department, Dr. A. Jurasz University Hospital</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-Pomorskie</state>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Niezgoda, M.D.</last_name>
      <phone>+48525854023</phone>
      <email>piotr.niezg@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Collegium Medicum w Bydgoszczy</investigator_affiliation>
    <investigator_full_name>Jacek Kubica</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Methoxyflurane</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

